Example: Heart Attack
Search clinical trials for: Reaferon
Total 0 results
We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
Medical Conditions
- COVID-19
- Biliary Tract Cancer (BTC)
- Chronic Proximal Humerus Dislocations
- Coagulation Defects, Other and Unspecified
- Colonic Carcinoma
- Drug Specific Antibodies
- Enterotoxigenic Escherichia Coli Infection
- Extraovarian Peritoneal Cancer
- Facial Angiofibromas
- Medulloblastoma; Unspecified Site
- Physician-Patient Relations
- Spondylitis
- Stroke Prophylaxis
- X-Linked Adrenoleukodystrophy
- View Full List
Sponsors and Collaborators
- Alexander Kolevzon
- Escola Superior de Enfermagem de Coimbra
- First Affiliated Hospital, Sun Yat-Sen University
- Institute of Cardiology Abidjan
- Jair Bar, M.D., Ph.D.
- Michigan Technological University
- NHS Greater Glasgow and Clyde
- National Institute of Health Research (NIHR) Mucosal Pathogens Research Unit (MPRU)
- National Rehabilitation Hospital, Ireland
- Proximagen, LLC
- Richard Wolf Medical Instruments Corporation (RWMIC)
- Sujata Vaidya
- University of Boras
- View Full List
Drug Interventions
- 1.0% Icotinib hydrochloride cream
- Estrogen Replacement Therapy
- Formulation M3
- Interferon beta 1a, oral doxycycline
- Iron Supplement,
- Ivermectin and Doxycycline
- Melatonin ("Circadin")
- Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
- TBR-652 75 mg
- Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.
- Zushima plaster with low dose
- cognitive function
- pertuzumab [Perjeta]
- View Full List
Conditions
Rare Diseases
Drug Interventions
Dietary Supplements
Sponsor/Collaborators
Locations